

NRF2 Is a Key Target for Prevention of Noise-Induced Hearing Loss by Reducing Oxidative Damage of Cochlea

Yohei Honkura^{1,2}, Hirotaka Matsuo^{3,*}, Shohei Murakami², Masayuki Sakiyama³, Kunio Mizutani⁴, Akihiro Shiotani⁴, Masayuki Yamamoto⁵, Ichiro Morita⁶, Nariyoshi Shinomiya³, Tetsuaki Kawase¹, Yukio Katori¹, Hozumi Motohashi^{2,*}

¹Department of Otolaryngology-Head & Neck Surgery, Tohoku University Graduate School of Medicine, 1-1 Seiryō-machi, Aoba-ku, Sendai, 980-8574, Japan.

²Department of Gene Expression Regulation, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryō-machi, Aoba-ku, Sendai, 980-8575, Japan.

³Department Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan.

⁴Department of Otolaryngology-Head and Neck Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan.

⁵Department of Medical Biochemistry, Tohoku University Graduate School of Medicine, 2-1 Seiryō-machi, Aoba-ku, Sendai, 980-8575, Japan.

⁶Department of Otolaryngology-Head and Neck Surgery, Self-Defense Forces Central Hospital, 1-2-24, Ikejiri, Setagaya, Tokyo 154-8532, Japan.

*To whom correspondence should be addressed: Hirotaka Matsuo and Hozumi Motohashi

Hirotaka Matsuo

Department of Integrative Physiology and Bio-Nano Medicine,
National Defense Medical College,

3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan

TEL: 81-4-2995-1482,

FAX: 81-4-2996-5187,

E-MAIL: hmatsuo@ndmc.ac.jp

Hozumi Motohashi

Department of Gene Expression Regulation,
Institute of Development, Aging and Cancer,

Tohoku University,

4-1 Seiryō-machi, Aoba-ku, Sendai, 980-8575, Japan

TEL: 81-22-717-8550,

FAX: 81-22-717-8554,

E-MAIL: hozumi.motohashi.a7@tohoku.ac.jp


SUPPLEMENTARY TABLE

Supplementary Table S1 | Sequences of primers for quantitative real-time PCR analysis.

Gene	Forward primer	Reverse primer	Probe
<i>Gapdh</i>	5'-GAGATGATGAC CCTTTTGGC-3'	5'-GTCGTGGAGTCT ACTGGTGTCTT-3'	-
<i>Nrf2</i>	5'-CAAGACTTGGG CCACTTAAAAGAC- 3'	5'-AGTAAGGCTTTC CATCCTCATCAC-3'	5'-FAM-AGGCGGC TCAGCACCTTGTA TCTTGA-TAMRA-3 ,
<i>Nqo1</i>	5'-AGCTGGAAGCT GCAGACCTG-3'	5'-CCTTTCAGAATG GCTGGCA-3'	5'-FAM-ATTTTCAGT TCCCATTGCAGTG GTTTGGG-TAMRA- 3'
<i>Ho-1</i>	5'-GTGATGGAGCG TCCACAGC-3'	5'-TTGGTGGCCTCC TTCAAGG-3'	5'-FAM-CGACAGC ATGCCCCAGGATT TGTC-TAMRA-3'
<i>Gclc</i>	5'-ATCTGCAAAGG CGGCAAC-3'	5'-ACTCCTCTGCAG CTGGCTC-3'	5'-FAM-ACGGGTG CAGCAAGGCCCA- TAMRA-3'
<i>Gclm</i>	5'-TGGAGCAGCTGT ATCAGTGG-3'	5'-AAATCTGGTGGC ATCACACA-3'	-
<i>Txnrd1</i>	5'-AGAAAGTGCTG GTCTTGGATTTTG-3 ,	5'-ACACGTTCCCTCC GAGACCC-3'	5'-FAM-TCTGGTCC CAAGAGGAGTCG GTGTG-TAMRA-3'

SUPPLEMENTARY FIGURES

Supplementary Figure S1 | Full-length immunoblot reacted with anti-NRF2 antibody shown in Figure 5b.



Supplementary Figure S2 | Full-length immunoblot reacted with anti-4-HNE antibody shown in Figure 6b.

